EMICIZUMAB PROPHYLAXIS IN INFANTS WITH SEVERE HEMOPHILIA A: MANAGEMENT OF 6 CASES

被引：0
|
作者：
Wang, Cassandra [1 ]
Kizilocak, Hande [1 ]
Young, Guy [1 ]
机构：
[1] Childrens Hosp Los Angeles, Ctr Thrombosis & Hemostasis, Los Angeles, CA USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
011
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
    Cohen, Omri
    Levy-Mendelovich, Sarina
    Budnik, Ivan
    Ludan, Noa
    Lyskov, Shani Kassia
    Livnat, Tami
    Avishai, Einat
    Efros, Orly
    Lubetsky, Aharon
    Lalezari, Shadan
    Misgav, Mudi
    Brutman-Barazani, Tami
    Kenet, Gili
    Barg, Assaf A.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (06)
  • [32] BUDGET IMPACT ANALYSIS OF RFVIII THERAPIES AND EMICIZUMAB FOR MANAGEMENT OF SEVERE HEMOPHILIA A
    Sun, S.
    Fan, T.
    Epstein, J.
    Ito, D.
    Xuan, D.
    VALUE IN HEALTH, 2019, 22 : S338 - S338
  • [33] Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
    Pipe, Steven W.
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kiialainen, Anna
    Chang, Tiffany
    Lehle, Michaela
    Fijnvandraat, Karin
    BLOOD, 2022, 140
  • [34] FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A
    Young, Guy
    Eakle, Katherine
    Lim, Elise
    Wang, Michael
    BLOOD, 2024, 144 : 2589 - 2590
  • [35] ECONOMIC IMPACT OF EMICIZUMAB PROPHYLAXIS FOR HEMOPHILIA A WITH AND WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S699 - S699
  • [36] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND INHIBITORS: A SYSTEMATIC REVIEW
    Camelo, R.
    Prudente, T. P.
    Minare, D. V.
    Gomes, G. D. P. V. C.
    Roberti, M. D. R. F.
    HAEMOPHILIA, 2023, 29 : 53 - 54
  • [37] Emicizumab: a novel drug in hemophilia A prophylaxis - a narrative review
    Mazurkiewicz, Lukasz
    Czernikiewicz, Krystian
    Rupa-Matysek, Joanna
    Gil, Lidia
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (10) : 933 - 942
  • [38] Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
    Rener, Karla
    Anzej Doma, Sasa
    Fink, Martina
    Podgornik, Helena
    Preloznik Zupan, Irena
    Cerchione, Claudio
    Zanon, Ezio
    HEMATOLOGY REPORTS, 2023, 15 (04) : 597 - 607
  • [39] Additional use of Factor VIII to a Patient with Severe Hemophilia a Receiving Emicizumab Prophylaxis from Infancy
    Yagi, Takeshi
    Matsuda, Takehiro
    Inamine, Itsuki
    Higa, Takeshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [40] Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
    Kim, Sung Eun
    Kim, Ji Yoon
    Park, Jeong A.
    Lyu, Chuhl Joo
    Hahn, Seung Min
    Han, Jung Woo
    Park, Young Shil
    BLOOD RESEARCH, 2024, 59 (01)
12345